Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) EBIAT (2016 - 2026)

Ani Pharmaceuticals' EBIAT history spans 16 years, with the latest figure at $27.5 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 367.52% to $27.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $78.3 million, a 522.94% increase, with the full-year FY2025 number at $78.3 million, up 522.94% from a year prior.
  • EBIAT hit $27.5 million in Q4 2025 for Ani Pharmaceuticals, up from $26.6 million in the prior quarter.
  • Over the last five years, EBIAT for ANIP hit a ceiling of $27.5 million in Q4 2025 and a floor of -$24.2 million in Q3 2024.
  • Historically, EBIAT has averaged -$595250.0 across 5 years, with a median of -$1.1 million in 2021.
  • Biggest five-year swings in EBIAT: crashed 23506.98% in 2022 and later surged 1165.25% in 2024.
  • Tracing ANIP's EBIAT over 5 years: stood at -$24.1 million in 2021, then surged by 82.42% to -$4.2 million in 2022, then surged by 127.22% to $1.2 million in 2023, then crashed by 989.7% to -$10.3 million in 2024, then soared by 367.52% to $27.5 million in 2025.
  • Business Quant data shows EBIAT for ANIP at $27.5 million in Q4 2025, $26.6 million in Q3 2025, and $8.5 million in Q2 2025.